Avalyn Pharma (NASDAQ:AVLN) Stock Rating Upgraded by Jefferies Financial Group

Avalyn Pharma (NASDAQ:AVLN) was upgraded by analysts at Jefferies Financial Group to a “strong-buy” rating in a research note issued on Monday,Zacks.com reports.

A number of other equities research analysts have also recently weighed in on AVLN. Wall Street Zen upgraded shares of Avalyn Pharma to a “hold” rating in a research report on Saturday, May 9th. Morgan Stanley initiated coverage on shares of Avalyn Pharma in a research report on Tuesday. They set an “overweight” rating and a $53.00 price target for the company. Guggenheim initiated coverage on shares of Avalyn Pharma in a research report on Monday. They set a “buy” rating and a $80.00 price target for the company. Finally, Evercore initiated coverage on shares of Avalyn Pharma in a research report on Tuesday. They set an “outperform” rating and a $51.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating and two have given a Buy rating to the company’s stock. According to data from MarketBeat, Avalyn Pharma currently has an average rating of “Strong Buy” and an average target price of $59.00.

Avalyn Pharma Stock Performance

Shares of AVLN stock opened at $26.70 on Monday. Avalyn Pharma has a twelve month low of $25.05 and a twelve month high of $32.22.

Insider Activity

In other Avalyn Pharma news, major shareholder Sr One Capital Management, Llc purchased 555,555 shares of Avalyn Pharma stock in a transaction dated Friday, May 1st. The shares were acquired at an average price of $18.00 per share, with a total value of $9,999,990.00. Following the completion of the transaction, the insider owned 2,186,562 shares of the company’s stock, valued at $39,358,116. This trade represents a 34.06% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Jill Carroll purchased 277,778 shares of Avalyn Pharma stock in a transaction dated Friday, May 1st. The shares were acquired at an average cost of $18.00 per share, for a total transaction of $5,000,004.00. Following the transaction, the director directly owned 2,186,562 shares of the company’s stock, valued at approximately $39,358,116. This represents a 14.55% increase in their position. The disclosure for this purchase is available in the SEC filing.

Avalyn Pharma Company Profile

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.